ampicillin + amoxicillin (Ulm University)

Ampicillin + amoxicillin refers to a sequential antibiotic treatment regimen investigated by the University of Ulm for the management of hospitalized patients with non-severe community-acquired pneumonia (CAP). The regimen involves an initial course of intravenous ampicillin, a broad-spectrum aminopenicillin, followed by a transition to oral amoxicillin once clinical stability is achieved. Both agents function by binding to penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall, thereby inhibiting the transpeptidation step of peptidoglycan synthesis. This leads to cell wall weakening and osmotic lysis of the bacteria. This sequential switch therapy is designed to optimize clinical outcomes while facilitating earlier discharge from the hospital.

Other names

ampicillin/amoxicillinsequential ampicillin/amoxicillin therapy